Paul Lang
In Vitro Biology, Integrated Drug Discovery Head (US) Sanofi
Paul Lang is Head of U.S. In Vitro Biology, Integrated Drug Discovery at Sanofi, where he oversees multidisciplinary teams across biochemistry, pharmacology, structural biology, and data sciences. With more than 20 years of experience in drug discovery, he has advanced numerous programs from target identification through clinical candidate nomination and is recognized for building high-performing discovery organizations.
Seminars
For many organizations, identifying a molecular glue hit is only the first hurdle. Determining whether that hit is mechanistically meaningful, clinically relevant, and worth the significant investment required for optimization remains one of the field’s greatest challenges. Researchers increasingly recognize that no single screening technology is sufficient, leading to growing adoption of DELs, functional screening, in-cell discovery platforms, proteomics, and biophysical characterization methods. This workshop will examine how to construct robust screening and profiling cascades that distinguish genuine opportunities from false positives, establish confidence in mechanism of action, and support more informed go/no-go decisions throughout molecular glue discovery.
Join this workshop to:
- Compare DEL, functional, cellular, proteomic, and next-generation screening approaches to identify productive induced-proximity events and expand discovery beyond traditional cereblon-based degradation
- Design multi-parameter profiling cascades that evaluate cooperativity, selectivity, mechanism of action, and biological relevance using biophysical tools, proteomics, and disease-relevant cellular models
